DuPont de Nemours Inc Dossier - Source-backed chat

DuPont de Nemours Inc

DDNYSE

SectorMaterials

IndustrySpecialty Chemicals

Beta (adjusted)1.05

Intrinsic Value $84.85median of 5 methods · middle span $40-$131based on filings through 31 Mar 2026

Market Price $129.20Price as of 1 Oct 2026

OvervaluedIntrinsic value is 34% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $17.4B

Enterprise Value $19.9B

Shares Outstanding 135M diluted

Next Earnings Date5 Nov 2026

Last ex-dividend31 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

DuPont's post-separation portfolio is executing well: second-quarter 2026 organic sales rose 4%, operating EBITDA increased 6%, adjusted EPS increased 48%, and transaction-adjusted free cash flow conversion reached 127%. Management consequently raised full-year sales, operating EBITDA and adjusted EPS guidance. The constructive operating trajectory is balanced by valuation. Portfolio simplification, healthcare, industrial-water and aerospace demand, productivity, and capital returns support the thesis; PFAS liabilities, post-separation execution, end-market weakness and failure to deliver the 2028 framework remain the principal risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026

Low · most bearish analyst$156.00

Mean target$170.00

High · most bullish analyst$186.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$156.0020%

Organic growth falls below the medium-term framework as construction or other industrial markets weaken, while unfavorable mix, growth investment or input costs constrain margins. Cash conversion drops below management's objective, full-year adjusted EPS guidance is reduced, or PFAS and other legacy liabilities create incremental costs.

Base CaseCentral scenario

$170.0055%

Matches the consensus mean

DuPont delivers within its raised 2026 guidance and progresses toward the 2028 framework, with healthcare and water strength offsetting more cyclical construction and industrial exposures. Margin improvement and cash generation continue, but much of the execution improvement is reflected in the August 28 official closing quote.

Bull CaseUpside scenario

$186.0025%

DuPont exceeds raised 2026 guidance as healthcare, biopharma, industrial water, aerospace and electric-vehicle applications sustain growth. Productivity and favorable mix expand margins, cash conversion remains above the medium-term objective, and share repurchases enhance per-share outcomes.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter 2026 results exceeded guidance, with 4% organic sales growth, 6% operating EBITDA growth and 48% adjusted EPS growth.
Second-quarter transaction-adjusted free cash flow was $326 million with 127% conversion, and DuPont announced its intent to repurchase $250 million of shares in the third quarter.
The simplified portfolio is positioned around healthcare, water, construction and industrial markets, while management targets 3%-4% organic sales CAGR, 150-200 basis points of margin improvement, 8%-10% adjusted EPS CAGR and greater than 90% free cash flow conversion through 2028.

Key Investment Risks

DuPont continues to face uncertainty from shared PFAS costs, litigation, natural-resource-damage claims, remediation obligations and possible regulatory changes.
Realizing the intended benefits of the Qnity separation and Aramids divestiture depends on effective execution, transition-service management and avoidance of disputes or unanticipated costs.
Results remain exposed to cyclical and geographic end-market conditions; second-quarter disclosures identified Middle East water weakness, while prior-year disclosures identified construction-market weakness.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.